In advanced prostate cancer, rapid and successful drug development has resulted in multiple treatment options, requiring careful decision making for individual patients. Clinicians face the increasingly difficult task of choosing from multiple potentially effective treatments that are also costly and potentially toxic.
The inaugural Advanced Prostate Cancer Consensus Conference (APCCC) did provide a forum for discussion and debates on current treatment options for men with advanced prostate cancer. The conference concluded with voting by the panel on pre-defined consensus questions, targeting areas of primary clinical relevance. Following the conference a manuscript with containing the expert recommendations was published at Annals of Oncology.
APCCC 2017 will:
- Provide an update on the current standard of advanced prostate cancer management.
- Program will be highly educational, consisting of invited lectures, debates and discussions led by the panel of international and interdisciplinary prostate cancer experts.
- Will focus on “knowledge translation” by summarising and conceptualising the current standards of advanced prostate cancer management.
- The conference will culminate again on Saturday with an interdisciplinary expert consensus panel meeting that will discuss and vote on predefined questions relating to key areas where there is lack of evidence or conflict regarding the optimal treatment of men with advanced prostate cancer. Participants will be able to attend the panel meeting as part of the conference.
- The consensus summary will be again published after the meeting in a high impact medical journal.
- Attendees will be able to interact with panel members, facilitating and encouraging international collaboration.
The consensus summary is available and published in Annals of Oncology. Please find it also here for download
Please note that detailed voting results as well as conflict of interest statements of all panel members are available at Annals of Oncology as supplemental material.